Data updated: Jun 28, 2026
CARBON DIOXIDE, USP (carbon dioxide) · AIRGAS USA LLC
X-Ray Contrast Activity
Respiratory
Approved 2013-07-05
NDA
Small Molecule
18
Indications
--
Phase 3 Trials
13
Years on Market
Details
- Status
- Prescription
- First Approved
- 2013-07-05
- Routes
- INHALATION
- Dosage Forms
- GAS
Companies
AIRGAS USA LLC LINDE GAS EQUIP HAUN SPECIALTY GASES INC LISS AMERICA LLC MIDDLESEX GASES TECHNOLOGIES, INC. CONTINENTAL CARBONIC PRODUCTS, INC. DJB GAS SERVICES, INC MITCHELL WEDLING SUPPLY LINDE NORTH AMERICA INC WELDERS SUPPLY COMPANY OF LOUISVILLE INC NEXAIR LINDE MERCHANT PRODUCTIONS INC PRAXAIR INC GENERAL DISTRIBUTING COMPANY AIRGAS CARBONIC INC RELIANT HOLDINGS LTD CENTRAL WELDING SUPPLY ROBERTS OXYGEN CO INC A-OX WELDING SUPPLY CO, INC.
Active Ingredient: CARBON DIOXIDE
Website: ↗
CARBON DIOXIDE, USP Approval History
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
Original
New Indication
New Form
Label Update
19 FDA actions from 2013 to 2025
Aug 2017 ORIGINAL
Update
What CARBON DIOXIDE, USP Treats
18 FDA approvalsOriginally approved for its first indication in 2013 . Covers 18 distinct patient populations.
- Other (18)
Other
(18 approvals)- • Approved indication (Jul 2013)Letter
- • Approved indication (Jul 2013)Letter
- • Approved indication (Jul 2013)Letter
- • Approved indication (Sep 2013)Letter
- • Approved indication (May 2014)Letter
- • Approved indication (Aug 2017)
- • Approved indication (Jun 2019)Letter
- • Approved indication (Jul 2020)Letter
- • Approved indication (Oct 2021)Letter
- • Approved indication (Feb 2022)Letter
- • Approved indication (Apr 2022)Letter
- • Approved indication (Feb 2024)Letter
- • Approved indication (Aug 2024)Letter
- • Approved indication (Nov 2024)Letter
- • Approved indication (Feb 2025)Letter
- • Approved indication (Apr 2025)Letter
- • Approved indication (Jun 2025)Letter
- • Approved indication (Oct 2025) NewLetter
📋
Clinical Trial Registry
2 trials| Trial | Sponsor ID | Phase | Status | Title |
|---|---|---|---|---|
| NCT02473354 (OIRD) | Pro00060429 | Ph 1 | completed | Predictors of Opioid-Induced Respiratory Depression (OIRD) |
| NCT02113449 results posted | 202181 RH01910 | Ph 2 | completed | Market Potential of Carbon Dioxide Nasal Spray |
🔬
Pro Active Pipeline
Ongoing clinical trials by development phase
Loading...
⭐
Pro Key Completed Trials
Completed studies with published results, ranked by significance
Loading...
📊
Trial Timeline
Full development history with FDA approval milestones
|
Loading...
Understanding FDA Approval Types
| Count | Type | What it means |
|---|---|---|
| - | ORIG | Original approval - drug first enters market |
| - | SUPPL - Efficacy | New indication (new disease/condition approved) |
| - | SUPPL - Labeling | Label text changes (warnings, dosing updates) |
| - | SUPPL - Manufacturing | Production changes (new facility) |
| - | SUPPL - Chemistry | Formulation changes (new dosage strength) |
Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.
CARBON DIOXIDE, USP FDA Label Details
Track CARBON DIOXIDE, USP with TheraRadar Pro
Watchlist alerts, full database access, CSV exports across 14,000+ drugs.
Data Sources
Data sourced from official FDA and NIH databases. Click links to verify on original sources.